HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

1,181.182

+78.2577.10%

Number of Gainers:11

Number of Losers:- -

Number of Flat:2

PE:- -

High:1,190.165

Open:1,104.063

Low:1,104.063

Close:1,102.926

Volume:155.06M

Turnover:2.25B

Market Cap:194.07B

Float Cap:146.32B

Loading ...

Nomura Upgrades Angelalign Technology to Buy From Neutral, Adjusts Price Target to HK$79.89 From HK$66.71

MT Newswires Live

Sihuan Pharmaceutical Returns to Profitability with FY Net Income of 180 Million Yuan

Sihuan Pharma FY25 revenue climbs 37.7% to RMB 2.6 billion

Sihuan Pharma - FY Profit Attributable RMB179.7 Mln

THOMSON REUTERS

Sihuan Pharma - Final Cash Dividend of RMB0.96 Cents per Share

THOMSON REUTERS

3SBio (SEHK:1530) Valuation Check After Strong 2025 Sales And Earnings Growth

Simply Wall St.

ANGELALIGN Grants 123,800 Restricted Share Units and 300,000 Share Options

3SBIO Reports Fiscal Year Profit Attributable to Owners Soars 305.8% to RMB 8.482 Billion

Angelalign grants 123,753 RSUs under post-IPO incentive scheme

3SBio proposes final dividend of HKD 0.25 per share

3SBio FY25 net profit jumps to RMB 8.5 billion; revenue rises 94.3% to RMB 18 billion

Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million

Angelalign Technology's Profit Climbs Sharply in 2025; Shares Jump 6%

MT Newswires Live

From Clinical Trust to Standard Definition: ANGELALIGN (06699) Builds Dual Moat with Globalization and China's Lower-Tier Market Strategy

ANGELALIGN Shares Surge Nearly 9% Following Strong Annual Results

Angelalign Technology (SEHK:6699) Earnings Surge Challenges Concerns Over Long Term Decline

Simply Wall St.

Press Release: Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth

Raily Aesmed Reports Annual Profit Turnaround with 1.87 Million Yuan Net Income

RAILY AESMED Appoints Dr. Lin Hai as Independent Non-Executive Director

Raily Aesthetic Medicine International Holdings FY2025 profit rises to RMB0.34 cents per share; revenue falls 5% to RMB189 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1593/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1181.1824,"timestamp":1775030909029,"preClose":1102.9258,"halted":0,"volume":155060188,"delay":0,"changeRate":0.070954,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":78.256592,"latestTime":"04-01 16:00:00","open":1104.0627,"high":1190.1648,"low":1104.0627,"amount":2254840894,"amplitude":0.078067,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775093400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1775007000000,1775016000000],[1775019600000,1775030400000]],"pbRate":1.451493,"peRate":13.229791,"turnoverRate":0.007651,"increases":11,"decrements":0,"flats":2,"marketCap":194072383424,"floatMarketCap":146322055680},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1190.1648,"amplitude":0.078067,"preClose":1102.9258,"low":1104.0627,"pbRate":"1.451493","latestPrice":1181.1824,"volume":155060188,"delay":0,"open":1104.0627,"prevYearClose":1094.978,"prevWeekClose":1118.805,"prevMonthClose":1102.926,"prevQuarterClose":1102.926,"fiveDayClose":1080.672,"twentyDayClose":1019.607,"sixtyDayClose":1115.318,"secType":"PLATE","market":"HK","turnoverRate":0.007651,"peRate":13.229791,"marketCap":194072383424,"floatMarketCap":146322055680,"timestamp":1775030909029,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":11,"down":0,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623430510","title":"Nomura Upgrades Angelalign Technology to Buy From Neutral, Adjusts Price Target to HK$79.89 From HK$66.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2623430510","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623430510?lang=en_us&edition=fundamental","pubTime":"2026-03-31 14:56","pubTimestamp":1774940168,"startTime":"0","endTime":"0","summary":"Angelalign Technology (HKG:6699) has an average rating of overweight and mean price target of HK$88.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic rese","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06699","BK1593","BK1587","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129525813","title":"Sihuan Pharmaceutical Returns to Profitability with FY Net Income of 180 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1129525813","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129525813?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:18","pubTimestamp":1774930711,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical (00460) announced its annual results for the period ended December 31, 2025. Total revenue reached approximately RMB 2.618 billion, representing an increase of about 37.7%...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1191","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623437405","title":"Sihuan Pharma FY25 revenue climbs 37.7% to RMB 2.6 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2623437405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623437405?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:01","pubTimestamp":1774929698,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical swung to profit of RMB 185 million for 2025, reversing a loss a year earlier.Revenue climbed 37.7% to RMB 2.6 billion, driven primarily by medical aesthetics.Operating profit rose to RMB 607 million, helped by higher medical aesthetics sales, tighter cost control, and improved innovative drug revenue.Board proposed a final cash dividend of RMB 0.96 cents per share; cash and equivalents, wealth management products, pledged deposits, and time deposits totaled RMB 4.4 billion at year-end.Group guided 2026 as the first year of a new three-year plan, targeting deeper domestic penetration and faster overseas expansion in medical aesthetics while accelerating innovative drug commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL6CDSrG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00460","BK1600","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623051374","title":"Sihuan Pharma -  FY Profit Attributable RMB179.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623051374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623051374?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:01","pubTimestamp":1774929694,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40I1AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1593","BK1191","BK1600","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623034374","title":"Sihuan Pharma -  Final Cash Dividend of RMB0.96 Cents per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623034374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623034374?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:01","pubTimestamp":1774929662,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLXC00322:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00460","BK1191","BK1515","BK1593","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623132199","title":"3SBio (SEHK:1530) Valuation Check After Strong 2025 Sales And Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2623132199","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623132199?lang=en_us&edition=fundamental","pubTime":"2026-03-31 03:06","pubTimestamp":1774897576,"startTime":"0","endTime":"0","summary":"3SBio (SEHK:1530) just released full year 2025 results, reporting sales of CNY 17,695.75 million and net income of CNY 8,482.16 million, drawing fresh attention to the stock’s recent move.\nSee our latest analysis for 3SBio.\nThe earnings release follows a board meeting earlier in March that highlighted these results and a potential final dividend. The strong full year figures appear to align with fresh interest in the stock, with a 7 day share price return of 13.25% and a 1 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-valuation-check-after-strong-2025-sales-and-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-valuation-check-after-strong-2025-sales-and-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","BK1593","BK1161","01530","DCF","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137700401","title":"ANGELALIGN Grants 123,800 Restricted Share Units and 300,000 Share Options","url":"https://stock-news.laohu8.com/highlight/detail?id=1137700401","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137700401?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:54","pubTimestamp":1774886054,"startTime":"0","endTime":"0","summary":"ANGELALIGN (06699) has announced the granting of awards to key employees as long-term incentives. On March 30, 2026, the company issued 123,800 restricted share units under its post-IPO restricted...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1100","BK1593","06699","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194363500","title":"3SBIO Reports Fiscal Year Profit Attributable to Owners Soars 305.8% to RMB 8.482 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1194363500","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194363500?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:32","pubTimestamp":1774881158,"startTime":"0","endTime":"0","summary":"3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1583","01530","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623634995","title":"Angelalign grants 123,753 RSUs under post-IPO incentive scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2623634995","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623634995?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:32","pubTimestamp":1774881156,"startTime":"0","endTime":"0","summary":"Angelalign granted restricted share units covering 123,753 shares under its post-IPO RSU scheme on March 30, 2026.Angelalign also granted share options for 300,000 shares under its post-IPO share option scheme on March 30, 2026.Option exercise price set at HK$ 72.85 per share.Options run for 10 years from grant date.Shares available for future grant total 4,520,036 under post-IPO share option scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelalign Technology Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9F2Rsy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1587","06699","BK1593","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623458783","title":"3SBio proposes final dividend of HKD 0.25 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623458783","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623458783?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:36","pubTimestamp":1774877785,"startTime":"0","endTime":"0","summary":"3SBio proposed a final dividend for fiscal 2025 of HKD 0.25 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2Zf5Lf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1593","BK1583","01530","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345381","title":"3SBio FY25 net profit jumps to RMB 8.5 billion; revenue rises 94.3% to RMB 18 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345381","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345381?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:36","pubTimestamp":1774877770,"startTime":"0","endTime":"0","summary":"3SBio posted net profit attributable to owners of parent up 305.8% to RMB 8.5 billion for year ended Dec. 31, 2025.Board proposed final dividend of HKD 0.25 per share.Pipeline and corporate updates included out-licensing PD-1/VEGF bispecific antibody 707 to Pfizer with USD 1.25 billion upfront payment; company also advanced Mandi spin-off plan with HKEx application submitted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9gwHKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","SG9999001176.USD","LU0321505439.SGD","BK4581","IE00BBT3K403.USD","SG9999002232.USD","SG9999001176.SGD","LU1883839398.USD","IE00BLSP4239.USD","LU0306806265.USD","LU1894683348.USD","IE00BLSP4452.SGD","LU1057294990.SGD","LU1894683264.USD","HK0000165453.HKD","LU0225284248.USD","BK4588","BK4533","LU1066051498.USD","BK1161","LU0456855351.SGD","01530","IE000M9KFDE8.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0170899867.USD","LU0122379950.USD","LU0225771236.USD","BK4599","IE00B19Z3581.USD","BK4592","LU0868494617.USD","BK1583","BK4568","SG9999011175.SGD","SG9999013999.USD","LU0306807586.USD","LU1066053197.SGD","SG9999003800.SGD","BK4550","BK4534","BK4585","LU0234572021.USD","LU0289739699.SGD","SG9999002224.SGD","IE0002270589.USD","SGXZ57979304.SGD","LU0321505868.SGD","BK4007","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315221","title":"Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315221?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:58","pubTimestamp":1774864687,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical posted a net loss of RMB 250 million, narrowing 55.9%.Operating expenses fell 56.6% to RMB 250 million.Commercial rollout accelerated with two oncology launches in 2025, while cash and cash equivalents climbed to RMB 650 million following the October IPO.For 2026, focus remains on expanding NRDL access, advancing indication expansions and pipeline development, while tightening cost management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL414TVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","02575","BK1593","BK1191","BK1515","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623398150","title":"Angelalign Technology's Profit Climbs Sharply in 2025; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623398150","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623398150?lang=en_us&edition=fundamental","pubTime":"2026-03-30 12:04","pubTimestamp":1774843463,"startTime":"0","endTime":"0","summary":"Angelalign Technology's  profit attributable to owners of the company rose to $28.4 million for 2025, from $12.1 million a year earlier, according to a March 27 Hong Kong bourse filing.Shares of the teeth aligner maker were up more than 6% in Monday morning trade.Earnings per share came in at $0.17, compared with $0.07 a year earlier.Revenue rose 38% to $370.3 million from $268.8 million in 2024.The board recommended a final dividend of HK$0.48 per share and a special dividend of HK$4.99 per share, subject to shareholder approval, with payment expected on June 8 to shareholders on record as of May 28.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1100","BK1593","BK1587","06699","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124986186","title":"From Clinical Trust to Standard Definition: ANGELALIGN (06699) Builds Dual Moat with Globalization and China's Lower-Tier Market Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1124986186","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124986186?lang=en_us&edition=fundamental","pubTime":"2026-03-30 11:37","pubTimestamp":1774841830,"startTime":"0","endTime":"0","summary":"On March 27, ANGELALIGN (06699) disclosed its 2025 annual results, which not only surpassed market expectations but also revealed the underlying logic of its globalization strategy as the industry...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","BK1593","BK1100","06699"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107213365","title":"ANGELALIGN Shares Surge Nearly 9% Following Strong Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1107213365","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107213365?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:08","pubTimestamp":1774836521,"startTime":"0","endTime":"0","summary":"ANGELALIGN (06699) saw its shares rise nearly 9% during the morning session. At the time of writing, the stock was up 6.24%, trading at HKD 70.7, with a turnover of HKD 26.63 million. The company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4588","BK1593","06699","BK1100","BK4585","VXUS","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623627331","title":"Angelalign Technology (SEHK:6699) Earnings Surge Challenges Concerns Over Long Term Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2623627331","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623627331?lang=en_us&edition=fundamental","pubTime":"2026-03-29 09:12","pubTimestamp":1774746777,"startTime":"0","endTime":"0","summary":"Angelalign Technology (SEHK:6699) opened FY 2025 with first half revenue of US$161.4 million and basic EPS of US$0.09, setting up its latest earnings release against a year of sharply higher reported earnings and a stronger net profit margin. The company has seen revenue move from US$121.3 million and EPS of US$0.02 in 1H 2024 to US$150.8 million and EPS of US$0.05 in 2H 2024, while trailing twelve month EPS reached US$0.17 and net profit margin improved to 7.7%, which points to cleaner...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-earnings-surge-challenges-con","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-earnings-surge-challenges-con","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","BK1587","BK1100","BK1593","06699"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622870986","title":"Press Release: Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622870986","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622870986?lang=en_us&edition=fundamental","pubTime":"2026-03-28 03:56","pubTimestamp":1774641360,"startTime":"0","endTime":"0","summary":"Angelalign Technology Inc.   released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel's passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said.Fox Hu, CEO of Angel, stated: \"The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel's open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melting pot of ideas and people is drivin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK1583","BK1593","BK1587","06699","TM","03160","BK4099","BK4604","BK4555","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131647160","title":"Raily Aesmed Reports Annual Profit Turnaround with 1.87 Million Yuan Net Income","url":"https://stock-news.laohu8.com/highlight/detail?id=1131647160","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131647160?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:34","pubTimestamp":1774629258,"startTime":"0","endTime":"0","summary":"Raily Aesmed (02135) announced its full-year financial results for the fiscal year ended December 31, 2025. The group recorded revenue of 189 million yuan, representing a decrease of 4.98% compared...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02135","BK1593","BK1209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155361646","title":"RAILY AESMED Appoints Dr. Lin Hai as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1155361646","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155361646?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:34","pubTimestamp":1774629255,"startTime":"0","endTime":"0","summary":"Dr. Lin Hai has been appointed as an independent non-executive director of RAILY AESMED (02135), effective March 27, 2026. Mr. Cao Dequan has resigned from his position as independent non-executive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","02135","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873417","title":"Raily Aesthetic Medicine International Holdings FY2025 profit rises to RMB0.34 cents per share; revenue falls 5% to RMB189 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873417","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622873417?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:03","pubTimestamp":1774623827,"startTime":"0","endTime":"0","summary":"Raily Aesthetic Medicine International Holdings FY2025 profit rises to RMB0.34 cents per share; revenue falls 5% to RMB189 million. Raily Aesthetic Medicine published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB189.4 million, down 5.0%.Gross profit was RMB77.7 million, up 8.8%, and gross margin was 41.0%, up 5.2 percentage points.Loss for the year narrowed to RMB2.2 million from RMB63.3 million, while profit attributable to owners of the parent was RMB1.9 million.Aesthetic medical services revenue rose 7.6% to RMB152.9 million, while aesthetic medical equipment products revenue fell 42.6% to RMB32.8 million due to product mix adjustments and the time required to promote new products.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL53K95B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","02135","BK1209"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":92,"code":"91000000","status":"200"}]}}